Difference between revisions of "FEMA5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
(11 intermediate revisions by the same user not shown) | |||
Line 6: | Line 6: | ||
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | ||
+ | |||
+ | __TOC__ | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
|+<big>WHO Classification of Female Genital Tumours (5th Edition) Content</big> | |+<big>WHO Classification of Female Genital Tumours (5th Edition) Content</big> | ||
Line 16: | Line 18: | ||
!'''Date of Last Editor Review''' | !'''Date of Last Editor Review''' | ||
!'''Notes''' | !'''Notes''' | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 2 (TUMOURS OF THE OVARY) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[FEMA5:Serous_cystadenoma,_adenofibroma,_and_surface_papilloma_of_the_ovary|Serous cystadenoma, adenofibroma, and surface papilloma of the ovary]] | |[[FEMA5:Serous_cystadenoma,_adenofibroma,_and_surface_papilloma_of_the_ovary|Serous cystadenoma, adenofibroma, and surface papilloma of the ovary]] | ||
Line 786: | Line 809: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 3 (ENDOMETRIOSIS AND RELATED CONDITIONS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[FEMA5:Endometriosis_and_derived_tumours|Endometriosis and derived tumours]] | |[[FEMA5:Endometriosis_and_derived_tumours|Endometriosis and derived tumours]] | ||
Line 797: | Line 841: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 4 (TUMOURS OF THE PERITONEUM) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[FEMA5:Adenomatoid_tumour_|Adenomatoid tumour]] | |[[FEMA5:Adenomatoid_tumour_|Adenomatoid tumour]] | ||
Line 1,062: | Line 1,127: | ||
| | | | ||
|- | |- | ||
− | |[[FEMA5:Serous_adenofibroma_and_papilloma_of_the_fallopian_tube|Serous adenofibroma and papilloma of the fallopian tube]] | + | | |
− | |Disease | + | ==== CHAPTER 5 (TUMOURS OF THE FALLOPIAN TUBE) ==== |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[FEMA5:Serous_adenofibroma_and_papilloma_of_the_fallopian_tube|Serous adenofibroma and papilloma of the fallopian tube]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,215: | Line 1,301: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 6 (TUMOURS OF THE BROAD LIGAMENT AND OTHER UTERINE LIGAMENTS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[FEMA5:Leiomyoma_of_the_broad_ligament_and_other_uterine_ligaments|Leiomyoma of the broad ligament and other uterine ligaments]] | |[[FEMA5:Leiomyoma_of_the_broad_ligament_and_other_uterine_ligaments|Leiomyoma of the broad ligament and other uterine ligaments]] | ||
Line 1,303: | Line 1,410: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 7 (TUMOURS OF THE UTERINE CORPUS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[FEMA5:Endometrial_hyperplasia_without_atypia|Endometrial hyperplasia without atypia]] | |[[FEMA5:Endometrial_hyperplasia_without_atypia|Endometrial hyperplasia without atypia]] | ||
Line 1,623: | Line 1,751: | ||
| | | | ||
|- | |- | ||
− | |[[FEMA5:Exaggerated_placental_site_reaction|Exaggerated placental site reaction]] | + | | |
− | |Disease | + | ==== CHAPTER 8 (GESTATIONAL TROPHOBLASTIC DISEASE) ==== |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[FEMA5:Exaggerated_placental_site_reaction|Exaggerated placental site reaction]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,732: | Line 1,881: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 9 (TUMOURS OF THE UTERINE CERVIX) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[FEMA5:Squamous_metaplasia|Squamous metaplasia]] | |[[FEMA5:Squamous_metaplasia|Squamous metaplasia]] | ||
Line 2,073: | Line 2,243: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 10 (TUMOURS OF THE VAGINA) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[FEMA5:Squamous_papilloma_of_the_vagina|Squamous papilloma of the vagina]] | |[[FEMA5:Squamous_papilloma_of_the_vagina|Squamous papilloma of the vagina]] | ||
Line 2,327: | Line 2,518: | ||
| | | | ||
|- | |- | ||
− | |[[FEMA5:Seborrhoeic_keratosis|Seborrhoeic keratosis]] | + | | |
− | |Disease | + | ==== CHAPTER 11 (TUMOURS OF THE VULVA) ==== |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[FEMA5:Seborrhoeic_keratosis|Seborrhoeic keratosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 2,535: | Line 2,747: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 12 (NEUROENDOCRINE NEOPLASIA) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[FEMA5:Neuroendocrine_tumour|Neuroendocrine tumour]] | |[[FEMA5:Neuroendocrine_tumour|Neuroendocrine tumour]] | ||
Line 2,579: | Line 2,812: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 13 (HAEMATOLYMPHOID PROLIFERATIONS AND NEOPLASIA) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[FEMA5:Florid_reactive_lymphoid_hyperplasia|Florid reactive lymphoid hyperplasia]] | |[[FEMA5:Florid_reactive_lymphoid_hyperplasia|Florid reactive lymphoid hyperplasia]] | ||
Line 2,646: | Line 2,900: | ||
| | | | ||
|- | |- | ||
− | |[[FEMA5:Lipoma_|Lipoma]] | + | | |
− | |Disease | + | ==== CHAPTER 14 (MESENCHYMAL TUMOURS OF THE LOWER GENITAL TRACT) ==== |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[FEMA5:Lipoma_|Lipoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 2,943: | Line 3,218: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ==== CHAPTER 15 (MELANOCYTIC LESIONS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | |[[FEMA5: | + | |[[FEMA5:Acquired_melanocytic_naevus|Acquired melanocytic naevus]] |
|Disease | |Disease | ||
| | | | ||
Line 2,965: | Line 3,250: | ||
| | | | ||
|- | |- | ||
− | |[[FEMA5: | + | |[[FEMA5:Congenital_melanocytic_naevus_|Congenital melanocytic naevus]] |
|Disease | |Disease | ||
| | | | ||
Line 2,976: | Line 3,261: | ||
| | | | ||
|- | |- | ||
− | |[[FEMA5: | + | |[[FEMA5:Blue_naevus_|Blue naevus]] |
|Disease | |Disease | ||
| | | | ||
Line 2,987: | Line 3,272: | ||
| | | | ||
|- | |- | ||
− | |[[FEMA5: | + | |[[FEMA5:Atypical_melanocytic_naevus_of_genital_type_|Atypical melanocytic naevus of genital type]] |
|Disease | |Disease | ||
| | | | ||
Line 2,998: | Line 3,283: | ||
| | | | ||
|- | |- | ||
− | |[[FEMA5: | + | |[[FEMA5:Dysplastic_melanocytic_naevus_|Dysplastic melanocytic naevus]] |
|Disease | |Disease | ||
| | | | ||
Line 3,009: | Line 3,294: | ||
| | | | ||
|- | |- | ||
− | |[[FEMA5: | + | |[[FEMA5:Mucosal_melanoma_|Mucosal melanoma]] |
|Disease | |Disease | ||
| | | | ||
Line 3,020: | Line 3,305: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ==== CHAPTER 16 (METASTASIS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | |[[FEMA5: | + | |[[FEMA5:Metastasis_to_the_lower_female_genital_tract|Metastasis to the lower female genital tract]] |
|Disease | |Disease | ||
| | | | ||
Line 3,042: | Line 3,337: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ==== CHAPTER 17 (GENETIC TUMOUR SYNDROMES OF THE FEMALE GENITAL TRACT) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[FEMA5:BRCA1/2-associated_hereditary_breast_and_ovarian_cancer_syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]] | ||
+ | |Disease | ||
+ | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[FEMA5:Lynch_syndrome|Lynch syndrome]] | ||
+ | |Disease | ||
+ | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[FEMA5:Cowden_syndrome|Cowden syndrome]] | ||
+ | |Disease | ||
+ | |[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
|- | |- | ||
|[[FEMA5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | |[[FEMA5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[FEMA5:Peutz-Jeghers_syndrome|Peutz-Jeghers syndrome]] | |[[FEMA5:Peutz-Jeghers_syndrome|Peutz-Jeghers syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[FEMA5:Ataxia-telangiectasia|Ataxia-telangiectasia]] | |[[FEMA5:Ataxia-telangiectasia|Ataxia-telangiectasia]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[FEMA5:Carney_complex|Carney complex]] | |[[FEMA5:Carney_complex|Carney complex]] | ||
Line 3,099: | Line 3,437: | ||
|[[FEMA5:DICER1_syndrome_|DICER1 syndrome]] | |[[FEMA5:DICER1_syndrome_|DICER1 syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[FEMA5:Ovarian_dysgenesis|Ovarian dysgenesis]] | |[[FEMA5:Ovarian_dysgenesis|Ovarian dysgenesis]] | ||
Line 3,120: | Line 3,458: | ||
|- | |- | ||
|[[FEMA5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] | |[[FEMA5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] | ||
+ | |Disease | ||
+ | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |- | ||
+ | |[[FEMA5:Hereditary_leiomyomatosis_and_renal_cell_carcinoma|Hereditary leiomyomatosis and renal cell carcinoma]] | ||
|Disease | |Disease | ||
| | | | ||
Line 3,130: | Line 3,479: | ||
| | | | ||
|- | |- | ||
− | |[[FEMA5: | + | |[[FEMA5:Other genetic tumour syndromes of the female genital tract|Other genetic tumour syndromes of the female genital tract]] |
|Disease | |Disease | ||
| | | |
Latest revision as of 14:14, 10 September 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.